Insider Selling: Kenvue (NYSE:KVUE) General Counsel Sells 38,491 Shares of Stock

Kenvue Inc. (NYSE:KVUE) General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kenvue Price Performance

KVUE traded up $0.30 during trading hours on Tuesday, hitting $17.47. The company’s stock had a trading volume of 23,712,274 shares, compared to its average volume of 33,988,625. The business’s 50-day moving average price is $17.59 and its 200-day moving average price is $17.27. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $24.35. The stock has a market cap of $33.54 billion, a price-to-earnings ratio of 20.55, a P/E/G ratio of 1.61 and a beta of 0.55. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.76%. The company had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the previous year, the business posted $0.24 earnings per share. Kenvue’s quarterly revenue was up 4.5% on a year-over-year basis. Sell-side analysts expect that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th will be given a dividend of $0.2075 per share. The ex-dividend date is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s payout ratio is 97.65%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Elyxium Wealth LLC bought a new position in Kenvue during the 4th quarter worth about $26,000. Physician Wealth Advisors Inc. grew its holdings in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares in the last quarter. Cornerstone Planning Group LLC grew its holdings in Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares in the last quarter. NBT Bank N A NY grew its holdings in Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after acquiring an additional 1,006 shares in the last quarter. Finally, MV Capital Management Inc. bought a new position in Kenvue during the 4th quarter worth about $28,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on KVUE. Barclays cut their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday. Argus upgraded shares of Kenvue to a “hold” rating in a research report on Friday, March 6th. Citigroup cut their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Finally, Canaccord Genuity Group boosted their price objective on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.